Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer

Intrinsic and acquired resistance to targeted therapies is a significant clinical problem in cancer. We previously showed that resistance to regorafenib, a multi-kinase inhibitor for treating colorectal cancer (CRC) patients, can be caused by mutations in the tumor suppressor FBW7, which block degra...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xiangping, Shen, Lin, Tong, Jingshan, Kuang, Chaoyuan, Zeng, Shan, Schoen, Robert E., Yu, Jian, Pei, Haiping, Zhang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381732/
https://www.ncbi.nlm.nih.gov/pubmed/32724460
http://dx.doi.org/10.7150/thno.45363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381732/
https://www.ncbi.nlm.nih.gov/pubmed/32724460
http://dx.doi.org/10.7150/thno.45363

Ejemplares similares